Final answer:
The combination of statins with fibrate acid derivatives increases the risk of rhabdomyolysis, a potentially serious condition that involves the breakdown of muscle tissue.
Step-by-step explanation:
A patient who is currently taking a statin may have a higher risk for developing rhabdomyolysis when also taking a fibrate acid derivative. Statins are HMG-CoA reductase inhibitors that reduce cholesterol levels, hence lowering cardiovascular risk. However, when combined with fibrate acid derivatives, which are also used to manage lipid levels, there is a notably increased risk of myopathy and rhabdomyolysis. This potentially serious side effect should be closely monitored by healthcare providers.